Every vector system currently available for gene therapy has some drawbacks and advantages. 1 The use of viral vectors such as retroviral and lentiviral vectors allow for the improved duration of therapeutic gene expression by the facile integration of them into the host genome, but are plagued by safety concerns such as malignant transformation. On the other hand, nonviral vectors are recognized to be nonpathogenic, while less efficient at introducing and maintaining the transgene expression. Artificially engineered human chromosomes are maintained independent of the host chromosome through a set of cell divisions. 2 Accordingly, the host genome is not disrupted, and the expression of the transgene could be sustained for a prolonged period without suffering the effects of its surrounding sequence on the host genome. These are the ideal properties required for vectors in gene therapy, and therefore the utilization of human artificial chromosomes (HACs) could circumvent the issues of conventional vectors.
There are two basic strategies to construct HAC vectors: 2 to manipulate a natural human chromosome for generating size-reduced minichromosomes (topdown), and to assemble a new chromosome de novo from its constituent DNA elements (bottom-up). Based on our findings that human chromosomes can be utilized as a vector for animal transgenesis, 3, 4 we have developed the methodology to generate top-down HACs by manipulating human chromosomes with telomere-directed chromosome truncation and homologous recombination in chicken DT40 cells. 5 Using this technology, our group recently constructed a novel human chromosome 21-derived HAC vector (21DpqHAC vector), 6 which was devoid of most expressed genes by telomere truncation at the genomic regions proximal to the centromere in both p (at AL163201 locus) and q (AL163204 locus) arms. A loxP sequence was then introduced into the q arm (at AL163203 locus) of the 21DpqHAC vector, which permits the site-specific insertion of circular DNA containing the transgene expression unit by the Cre-loxP system ( Figure  1a) . We also showed the microcell-mediated chromosome transfer (MMCT) 7, 8 into an immortalized human fibrosarcoma cell line (HT1080) and the mitotic stability and persistent expression of EGFP gene in the resultant HT1080 clones.
An autotransplantation of ex vivo transduced normal human primary fibroblasts (hPFs) with the transgene of interest is a potential approach in replacement therapy for hormone or metabolic enzyme deficiencies, because the hPFs could be readily obtained from patients and cultured for further genetic modifications. However, the ability of 21DpqHAC as a vector for ex vivo therapeutic gene delivery in human primary cells has not been evaluated in the above study. Here, we studied the introduction of the 21DpqHAC vector into normal hPFs with MMCT, 7, 8 which is recognized as the most suitable method for the transfer of a single, intact chromosome from one cell to another and enabled the lower incidence of fragmentation and rearrangement of donor chromosomes compared to transfection-based methods. 9, 10 To our knowledge, this is the first report to demonstrate that the structurally defined, extra artificial chromosome is highly maintained in normal hPFs without accompanying aberration of host chromosomes. In the resultant hPFs carrying the HAC vector, we also showed the long-term expression of therapeutic transgene, human erythropoietin (EPO) as a model, which is a growth factor for erythroid cells and widely used for the clinical treatment of anemia in renal insufficiency. 11 Although the introduction of HACs derived from human chromosome 14 fragment (SC20) into normal bovine primary fibroblasts (bPFs) with MMCT was shown for preparing the donor cells of the somatic nuclear transfer to generate trans-chromosomic calves, 12 the retention and structure of the HACs in the transduced bPFs after a set of cell divisions remain to be elucidated because of the low transfer efficiency (approximately 1 to 10 Â 10 À6 in immortalized cells) 7 in MMCT and the limited cell division capacity of bPFs . To investigate the feasibility of minichromosome transfer into normal hPFs by MMCT, we employed HFL-1 cells (RCB0521, RIKEN, Tsukuba, Japan) as recipient hPFs and first examined the SC20 fragment, which contains neo r gene and was shown to be stable in various human and mouse cells. 13 It was under the condition of 45% polyethylene glycol 1500 containing 10% dimethyl sulfoxide in DMEM that the most frequently G418-resistant colonies were obtained (about 1.26 Â 10 À4 of the transduced cells), indicating that the neo r marker on the SC20 fragment could be transferred into normal hPFs and this efficiency was better when compared with that in immortalized cells. 7 In addition to HFL-1 cells, the SC20 fragment was also successfully transferred into the other normal hPFs, HUC-F2 cells and HF19 cells (RCB0436, RCB0210, RIKEN, Tsukuba, Japan, data not shown), suggesting that MMCT of minichromosomes could be applicable to a variety of hPFs from patients as well as above hPFs.
We then constructed the expression cassette of human epo gene, which is under the control of the CMV promoter and SV40 polyA signal, as an application example, and introduced them into the 21DpqHAC vector by Cre-loxP recombination in CHO (#21)-hyg4 cells 6 (EPO-21DpqHAC vector, Figure 1b ). We obtained 21 G418-resistant clones (named H4E cells), and all of which secreted EPO into conditioned media (250-520 IU/10 6 cells/6 days). The retention of markers for human chromosome 21 (D21S275, PRED65, PRED3) on the EPO-21DpqHAC vector was confirmed by PCR. To examine the structure and copy number of the EPO-21DpqHAC vector in H4E cells, fluorescence in situ hybridization (FISH) analysis was carried out on four clones using human Cot1 DNA as the probe. In all four clones, a single spot signal was observed in most of the metaphase specimens (93-99%, n ¼ 50 on each clone), indicating that the EPO-21DpqHAC vector was retained as a single copy per cell. No insertion or translocation or obvious size alteration of the EPO-21DpqHAC vector was observed cytogenetically. Then, we used one of H4E clones (H4Ec10) to transfer the resultant EPO21DpqHAC vector into HFL-1 cells with MMCT and obtained 16 colonies from five MMCT experiments under blasticidine-S (bsd) selection.
To assess the retention of the EPO-21DpqHAC vector in HFL-1 cells, the presence of the neo gene and the epo expression cassette was determined by PCR on 11 of 16 bsd-resistant clones (Figure 2a ). In addition, these 11 clones produced EPO into conditioned media (260-690 mIU/10 6 cells/24 h), indicating that the EPO- 6 The distal q arm was deleted from human chromosome 21 by telomere-directed truncation at AL163204 locus. For the site-directed insertion of the transgene of interest, a loxP sequence was introduced at AL163203 locus on the q arm. And then, the distal p arm was further deleted at AL163201 locus as with the q arm deletion. Triangle indicates artificially synthesized telomere sequence for telomere truncation. loxP, loxP sequence. (b) Schematic diagram of the introduction of the epo expression cassette into the loxP site on the 21DpqHAC vector. CMV, CMV promoter; epo, human EPO cDNA, neo, neomycin-resistant gene; and bsr, blasticidine-S-resistant gene. pLN1-EPO was constructed as follows: SV40 polyA sequence was amplified with primer pairs, 5 0 -CGGGATCCCTCGAGCGAGACATGATAAGATACA TTGATG-3 0 and 5 0 -GGAAGATCTTCCTAATCAGCCATACCACATTT GTAGAGG-3 0 , and pSTneoB 25 as a template DNA, using KOD-PLUS DNA polymerase (Toyobo, Osaka, Japan). This DNA fragment was digested with BamHI and BglII, and then cloned into the BamHI site of pBS226 (Gibco BRL, Grand Island, NY) as for pBS226-pA. CMV promoter sequence was amplified with primer pairs, 5 0 -CGGAATTCC GGACATTGATTATTGACTAGTTATTAATAG-3 0 and 5 0 -CGGGATCCC GGGTGTCTTCTATGGAGGTCAAAACAG-3 0 , and pBS226 as a template DNA, and then cloned into EcoRI-BamHI site of pBS226-pA as for pLN1. For pLN1-EPO, human EPO coding sequence was amplified with primer pairs, 5 0 -CGGGATCCCGGCCACCATGGGGGTGCACGAAT GTC-3 0 and 5 0 -CGCTCGAGCGCTATCTGTCCCCTGTCCTGCAGG-3 0 , and human epo cDNA as a template DNA, and then cloned into BamHIXhoI site of pLN1. Arrows with short-dashed line indicate XbaI digestion site for Southern blot analysis. Arrows indicate the primer positions for M13RV, SVNp1 and NeoRp2.
Usefulness of HAC in therapeutic gene delivery M Kakeda et al 21DpqHAC vector was successfully introduced into HFL-1 cells (HFL-1/EPO cells). To examine the structure of transferred EPO-21DpqHAC vector in HFL-1/EPO clones, FISH analysis was carried out on four clones probed with the human alphoid DNA sequence derived from the centromeric region of human chromosome 21 (21aDNA), 14 which is also hybridized with that of chromosome 13. In all of the four clones, one or two extra spot signals were observed independent of the four signals on the centromere of host chromosomes ( Figure   2b , Table 1 ). This clearly demonstrated the introduction of the EPO-21DpqHAC vector into normal hPFs. There is no evidence of any insertion or translocation of the vector sequence on host chromosomes or obvious size alteration of the EPO-21DpqHAC vector itself. Furthermore, no aberration of the epo expression cassette was confirmed by Southern blot analysis (Figure 3) . These results indicate that the karyotype of HFL-1/EPO clones was apparently normal and the overall structure of EPO21DpqHAC vector was not changed in these cells as with the observation in the HAC donor H4Ec10 cells. The EPO-21DpqHAC vector was retained at a constant copy number mostly in a single copy per cell (Table 1) , whereas in the case of the human X centromere-based minichromosomes their copy number per cell was increased when the overall size of the minichromosome was substantially reduced. 15 To investigate the mitotic stability of the EPO-21DpqHAC vector in normal hPFs, HFL/EPO clones were cultured and maintained in the absence of the selection drug, and then FISH analysis was carried out probed with 21aDNA. The retention rates of the EPO-21DpqHAC vector were initially 88.2 to 100% of metaphase, and after six to nine passages (around 10 to 14 PDL, 7 cells in six to nine passages, and then their growth stopped, suggesting that cell senescence occurred and the introduction of the EPO-21DpqHAC vector did not cause immortalization.
To evaluate how long the EPO-21DpqHAC vector allows the expression of human epo transgene, four HFL-1/EPO clones were cultured at a confluent monolayer, and the amount of EPO secreted in conditioned media was sequentially determined (Figure 4 ). For at least 12 weeks, the EPO expressions were sustained without loss or attenuation, and clone #1-1 provided the maximum EPO expression up to 18 IU/10 6 cells/24 h, demonstrating that the EPO-21DpqHAC vector is able to provide prolonged expression of the transgene in normal hPFs. The EPO expression gradually increased, correlating with the time course. Although the mechanism remains to be elucidated, it is known that transgene products are synthesized at increased rates in a confluent monolayer and under cell growth-arrested conditions. 20 During the preparation of this paper, the transfer of other bottom-up artificial chromosomes (ACEs) containing RFP gene into human primary mesenchymal stem cells (MSCs) by lipofection was reported. 21 Although the RFP expression and retention of ACEs were shown in a small population (7-15%) of the transduced MSCs up to 2-3 weeks, the long-term expression and mitotic stability of ACEs were not examined. In addition, the structure of RFP-ACEs and the copy number of introduced RFP gene were inconclusive. On the other hand, the structure of our 21DpqHAC vector is highly predictable from DNA .5% CO 2 , and washed with DMEM. Microcells purified from H4E cells (6 Â 10 7 cells) were overlaid on HFL-1 cells in DMEM containing 50 mg/ ml Phytohemagglutinin-P and incubated at 371C for 15 min. DMEM was then removed and 2 ml of 45% PEG1500-10% DMSO solution was added (PEG1500, Roche, Indianapolis, IN, USA; DMSO, Sigma, St Louis, MO, USA). After 1 min at room temperature, 45% PEG1500-10% DMSO solution was removed, and HFL-1 cells were washed with DMEM and cultured in DMEM containing 20% FBS for overnight. Cells were then replated onto five 48-well plates and selected under blasticidine-S (3 mg/ml) for 2 weeks. (a) PCR analysis for genomic DNA of HFL-1/EPO cells. Genome, genomic DNA of recipient HFL-1 cells, D2S1334, STS marker for human chromosome 2, neo, neomycin-resistant gene; and epo cassette, the expression cassette of human epo gene. Genomic DNAs were subjected to PCR using Ex Taq DNA polymerase (TaKaRa-bio, Otsu, Japan). Primer pairs were as follows: sequences of human chromosome 21. 22 The site-directed introduction of the epo expression cassette is also defined by the single loxP sequence, 6 which is supported in Figure 3 .
In a previous baboon ex vivo EPO-replacement model, baboon primary MSCs (bMSCs) transduced with human epo gene by a retroviral vector were encapsulated within subcutaneously implanted immunoisolation devices (0.81-6.6 Â 10 6 cells/kg), and EPO was secreted into the circulation showing a higher mean hematocrit than that of the control. 23 In this study, HFL-1/EPO clones could be expanded up to 3.8 Â 10 7 cells, which is comparable to the baboon model. Although the expression level of EPO in HFL-1/EPO clones (o18 IU/10 6 cells/24 h) was lower than that in the above bMSC system (183-712 IU/ 10 6 bMSCs/24 h), improved expression should be achieved by using the promoters and regulatory elements better suited for gene expression in normal hPFs. Thus, the MMCT is applicable to prepare large numbers of normal hPFs expressing therapeutic transgenes on the HACs.
One of the important issues for gene therapy vector is to establish physiological levels of transgene expression in specific cells or tissues for the appropriate period in a normally regulated manner. Further optimization of regulatory elements, such as hypoxia-responsive enhancer, which can be activated through the transcriptional complex hypoxia-inducible factor 1A, 24 might permit the physiological control of EPO expression in normal hPFs. 14 ; a human alphoid DNA probe from the centromeric region of chromosome 21. Mitotic-loss rates of the EPO-21DpqHAC vector were calculated by the following formula: N n ¼ N 0 Â (1ÀR) n , where N is the retention rate after 'n' generations, N 0 is the retention rate at day 0 and R is the loss rate per generation. Passages 6 and 9 were equivalent to 10 and 14 generations, respectively. Figure 3 Southern blot analysis for the epo expression cassette of HFL-1/ EPO clones. Genomic DNAs were digested with XbaI (Roche, Indianapolis, IN, USA) and applied to 0.8% agarose gel electrophoresis. Blotting and hybridization was carried out as described 3 using 32 P-labeled human epo cDNA probe. Arrow indicates the expected band size for the epo expression cassette.
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Our HAC vector could carry large-sized DNA, 5, 12 and therefore the utilization of genomic region including regulatory sequences and the gene of interest itself, such as insulin for diabetes and large genes for monogenic disorders, might establish physiological control of transgene expression.
In conclusion, this study shows the potential application of the 21DpqHAC vector in hormone-replacement gene therapy, which might ensure safety with no lesion of host chromosomes and provides long-term therapeutic transgene expression. This also implies that utilization of the HAC vector offers novel options for ex vivo gene therapy.
